Education
About Us
Working with TipRanks
Follow Us
Roche Holding (RHHBY)
OTHER OTC:RHHBY
RHHBY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$29.20 - $44.31
Previous CloseN/A
Volume3.10M
Average Volume (3M)5.04M
Market Cap
$235.32B
Enterprise Value$249.64B
Total Cash (Recent Filing)CHF5.38B
Total Debt (Recent Filing)CHF30.78B
Price to Earnings (P/E)24.4
Beta0.40
Next Earnings
Jul 24, 2025EPS Estimate
1.49Last Dividend Ex-Date
Mar 28, 2025Dividend Yield2.38%
Share Statistics
EPS (TTM)1.47
Shares Outstanding5,620,501,500
10 Day Avg. Volume2,763,869
30 Day Avg. Volume5,035,105
Financial Highlights & Ratios
PEG Ratio18.00
Price to Book (P/B)N/A
Price to Sales (P/S)3.70
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$42.67Price Target Upside15.01% Upside
Rating ConsensusHold
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentEarly trontinemab data shows competitive amyloid clearance and improved ARIA rate versus peers, highlighting its potential in the market.
Drug EfficacyGazyva showed potential best-in-class profile in lupus nephritis, likely making it the starter therapy of choice.
Financial PerformanceRoche's model was updated and numbers raised post recent business trends, with increased sales and EPS growth estimates.
Bears Say
Clinical TrialsThere was a case of fatal cerebral macrohemorrhage in Part 2, affecting the trontinemab trial's safety perception.
Safety ConcernsThe high placebo response rate in males was notable, where placebo achieved a higher complete renal response than Gazyva, potentially impacting its perceived effectiveness.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.62% Mutual Funds
0.11% Other Institutional Investors
99.22% Public Companies and
Individual Investors
RHHBY FAQ
What was Roche Holding’s price range in the past 12 months?
Roche Holding lowest stock price was $29.20 and its highest was $44.31 in the past 12 months.
What is Roche Holding’s market cap?
Roche Holding’s market cap is $235.32B.
When is Roche Holding’s upcoming earnings report date?
Roche Holding’s upcoming earnings report date is Jul 24, 2025 which is in 105 days.
How were Roche Holding’s earnings last quarter?
Roche Holding released its earnings results on Jan 30, 2025. The company reported $1.181 earnings per share for the quarter, beating the consensus estimate of $1.113 by $0.068.
Is Roche Holding overvalued?
According to Wall Street analysts Roche Holding’s price is currently Undervalued.
Does Roche Holding pay dividends?
Roche Holding pays a Annually dividend of $0.855 which represents an annual dividend yield of 2.38%. See more information on Roche Holding dividends here
What is Roche Holding’s EPS estimate?
Roche Holding’s EPS estimate is 1.49.
How many shares outstanding does Roche Holding have?
Roche Holding has 5,620,501,500 shares outstanding.
What happened to Roche Holding’s price movement after its last earnings report?
Roche Holding reported an EPS of $1.181 in its last earnings report, beating expectations of $1.113. Following the earnings report the stock price went up 2.522%.
Which hedge fund is a major shareholder of Roche Holding?
Currently, no hedge funds are holding shares in RHHBY
---
Roche Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$42.67 (15.01% Upside)
$42.67 (15.01% Upside)
Blogger Sentiment
Bullish
RHHBY Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 11.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.36%
12-Months-Change
Fundamentals
Return on Equity
26.76%
Trailing 12-Months
Asset Growth
4.51%
Trailing 12-Months
Company Description
Roche Holding
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
---
RHHBY Company Deck
---
RHHBY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Roche reported strong financial results for 2024 with significant growth in sales and core operating profit. The company successfully managed the decline in COVID-19 sales through robust base business growth and achieved key milestones in both the pharma and diagnostics segments. However, the net income decline due to impairments and challenges in some markets posed concerns. Overall, the sentiment leans positive with a strong pipeline and strategic focus on future growth.Read More>---
RHHBY Stock 12 Month Forecast
Average Price Target
$42.67
▲(15.01% Upside)
Technical Analysis
Best Analysts Covering RHHBY
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-5.80%
initiated a sell rating a year ago
Copying Mark Purcell's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -5.80% per trade.
---